According to Rob Hillman, CEO of ActivX Biosciences, the ability and technology to find low-abundance proteins is an art.
Enter the artist, David Campbell, in the new position of vice president of chemistry. Campbell, 42, began his career in biotech but until 1999 couldnt find the link between the new biology and his own specialty, chemistry. Ruedi Aebersolds paper on ICAT technology changed Campbells outlook. For the first time, I saw a role for chemistry in proteomics, he recalls.